From: The prognostic role of preoperative serum albumin levels in glioblastoma patients
Variable | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
P | HR | 95% CI | P | HR | 95% CI | |
Sex | 0.880 | 1.021 | 0.778-1.339 | 0.266 | 1.176 | 0.883-1.566 |
Age | 0.059 | 1.011 | 1.000-1.022 | 0.466 | 1.004 | 0.993-1.016 |
Tumor size | 0.474 | 1.002 | 0.997-1.007 | 0.381 | 1.002 | 0.997-1.008 |
KPS | <0.001 | 0.964 | 0.954-0.974 | <0.001 | 0.974 | 0.963-0.986 |
Resection | 0.014 | 0.731 | 0.568-0.940 | 0.091 | 0.800 | 0.618-1.036 |
Adjuvant treatment | <0.001 | 0.577 | 0.487-0.684 | 0.001 | 0.726 | 0.597-0.884 |
MGMT promoter | 0.162 | 0.823 | 0.626-1.081 | 0.925 | 1.015 | 0.749-1.375 |
IDH1-R132H mutation | 0.006 | 0.450 | 0.255-0.794 | 0.018 | 0.489 | 0.270-0.885 |
Serum albumin level | <0.001 | 0.938 | 0.912-0.964 | 0.023 | 0.966 | 0.938-0.995 |